Infomerics Upgrade Fredun Pharmaceuticals Credit Rating to BBB Plus; Boosts Financial Profile

The rating upgrade is a significant milestone that reflects FredunPharmaceuticals improved operational performance, stronger financial profile, and disciplined capital management across FY24 and FY25 (Audited).

The total bank facilities rated comprise:

• ₹143.17 crore – Long-Term Bank Facilities

• ₹13.00 crore – Long-Term/Short-Term Working Capital Facilities

The upgraded IVR BBB+ rating indicates an enhanced degree of safety regarding the timely servicing of financial obligations and demonstrates improving credit quality. The Stable outlook further signifies the rating agency’s confidence in the Company’s ability to sustain its performance trajectory and maintain a balanced financial risk profile.

Strategic Significance of the Upgrade

This development goes beyond a routine rating review. It represents:

• Strengthened banking confidence and institutional credibility

• Improved financial flexibility to support expansion initiatives

• Potential optimization of borrowing costs

• Enhanced positioning for future growth capital requirements

As Fredun Pharmaceuticals continues to expand its export presence across Africa, Southeast Asia, CIS countries, and Latin America, the upgraded credit rating strengthens its financial flexibility to efficiently manage working capital and support strategic growth initiatives.

The upgrade reflects the Company’s consistent revenue momentum, operational efficiency, and prudent leverage management, reinforcing its commitment to building a resilient, scalable, and globally competitive pharmaceutical platform.

Commenting on the update, Mr. Fredun Medhora, Managing Director, said, “This upgrade is encouraging for all of us at Fredun. It reflects the hard work of our team and the disciplined manner in which we are building the business. As we continue to grow across markets, our focus remains on strengthening the Company’s foundation while pursuing larger opportunities responsibly.”

Disclaimer: This article is for informational purposes only and does not constitute financial advice.